

APC anti-human CD11b Antibody

Catalog# / Size	301309 / 25 tests 301310 / 100 tests 301350 / 100 µg
Clone	ICRF44
Regulatory Status	RUO
Workshop	IV M047
Other Names	Integrin αM chain, C3biR, CR3, Mac-1, Mo1, ITGAM
Isotype	Mouse IgG1, κ
Description	CD11b is a 165-170 kD type I transmembrane glycoprotein also known as α _M integrin, Mac-1, CR3, and C3biR. CD11b non-covalently associates with integrin β ₂ (CD18) and is expressed on granulocytes, monocytes/macrophages, dendritic cells, NK cells, and subsets of T and B cells. CD11b/CD18 is critical for the transendothelial migration of monocytes and neutrophils. It is also involved in granulocyte adhesion, phagocytosis, and neutrophil activation. CD11b/CD18 interacts with ICAM-1 (CD54), ICAM-2 (CD102), ICAM-4, CD14, CD23, heparin, iC3b, fibrinogen, and factor X.

Product Details

Verified Reactivity	Human, Cynomolgus, Rhesus
Reported Reactivity	African Green, Baboon, Chimpanzee, Common Marmoset, Pig
Antibody Type	Monoclonal
Host Species	Mouse
Formulation	µg size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide. test sizes: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation	The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration	µg sizes: 0.2 mg/mL test sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application. For flow cytometric staining using the test sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
Excitation Laser	Red Laser (633 nm)
Application Notes	The ICRF44 antibody inhibits heterotypic adhesion of granulocytes in response to fMLP. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections, immunofluorescence microscopy ⁵ , stimulation of monocytes ³ , blocking of heterotypic PMN aggregation ⁸ , and blocking of granulocyte activation ¹² . This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 301361 & 301362).

Application References

(PubMed link indicates
BioLegend citation)

1. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York.
2. Barclay N, *et al.* 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego.
3. Rezzonico R, *et al.* 2001. *Blood* 97:2932. (Stim)
4. Marsik C, *et al.* 2003. *Shock* 20:493. (FC)
5. David A, *et al.* 2003. *J. Leukoc. Biol.* 74:551. (IF)
6. Charles N, *et al.* 2010. *Nat. Med.* 16:701. (FC) [PubMed](#)
7. Thurlow LR, *et al.* 2010. *Infect. Immun.* 128:1128. (FC) [PubMed](#)
8. Jadhav S, *et al.* 2001. *J. Immunol.* 167:5986. (Block)
9. Yoshino N, *et al.* 2000. *Exp. Anim. (Tokyo)* 49:97. (FC)
10. Sestak K, *et al.* 2007. *Vet. Immunol. Immunopathol.* 119:21. (FC)
11. Wen T, *et al.* 2014. *J Immunol.* 192:5481. (FC) [PubMed](#)
12. Sprong T, *et al.* 2003. *Blood* 102:3702. (Block)
13. Cash JL, *et al.* 2013. *EMBO Rep.* 14:999. (FC) [PubMed](#)
14. Larsson K, *et al.* 2015. *PNAS.* [PubMed](#)

Product Citations

1. Tripathi H, *et al.* 2020. *J Mol Cell Cardiol.* 149:95. [PubMed](#)
2. Paris J *et al.* 2019. *Cell Stem Cell.* 25(1):137-148. [PubMed](#)
3. Guo X, *et al.* 2016. *Mol Ther Methods Clin Dev.* 3:15054. [PubMed](#)
4. Schimek V, *et al.* 2022. *Cell Death Dis.* 13:113. [PubMed](#)
5. Richardson SE, *et al.* 2021. *STAR Protocols.* 2(2):100420. [PubMed](#)
6. Schwabenland M, *et al.* 2021. *Acta Neuropathol.* 142:923. [PubMed](#)
7. Saggi G, *et al.* 2018. *Nat Commun.* 9:5058. [PubMed](#)
8. André V, *et al.* 2012. *Blood Cancer J.* 2:94. [PubMed](#)
9. Hemkemeyer SA, *et al.* 2020. *J Biol Chem.* 296:100136. [PubMed](#)
10. Morton JJ, *et al.* 2018. *Mol Carcinog.* 57:1651. [PubMed](#)
11. Hünninger K, *et al.* 2015. *J Immunol.* 194:1199. [PubMed](#)
12. Wang E, *et al.* 2021. *Cell Stem Cell.* 28(4):718-731.e6. [PubMed](#)
13. Li Y, *et al.* 2022. *Cell Rep.* 38:110284. [PubMed](#)
14. Perelman SS, *et al.* 2021. *Nat Microbiol.* 6:731. [PubMed](#)
15. Dan H, *et al.* 2020. *Mol Oncol.* 14:795. [PubMed](#)
16. Eriksson E, *et al.* 2019. *J Immunol.* 202:787. [PubMed](#)
17. Szentkereszty M, *et al.* 2020. *Pathol Oncol Res.* 26:1117. [PubMed](#)
18. Berger M, *et al.* 2012. *J Biol Chem.* 287:19409. [PubMed](#)
19. Johnston G, *et al.* 2020. *Gene.* 752:144758. [PubMed](#)
20. Yang E, *et al.* 2021. *Exp Mol Med.* 53:1902. [PubMed](#)
21. Krampert L, *et al.* 2021. *Front Immunol.* 12:712948. [PubMed](#)
22. Velázquez-Avila M, *et al.* 2019. *Leukemia.* 33:1337. [PubMed](#)
23. Hazeldine J, *et al.* 2017. *PLoS Med.* 10.1371/journal.pmed.1002338. [PubMed](#)
24. Surdziel E, *et al.* 2017. *PLoS One.* 10.1371/journal.pone.0183679. [PubMed](#)
25. Zelter T, *et al.* 2022. *EMBO Rep.* 23:e53641. [PubMed](#)
26. Wegner J, *et al.* 2021. *Sci Rep.* 11:14983. [PubMed](#)
27. Wei Z, *et al.* 2021. *Nat Commun.* 0.805555556. [PubMed](#)
28. Hemkemeyer SA, *et al.* 2020. *J Biol Chem.* [PubMed](#)
29. Collado A, *et al.* 2021. *Front Pharmacol.* 12:656244. [PubMed](#)
30. Horn LA, *et al.* 2017. *Oncotarget.* 8:57964. [PubMed](#)
31. Kiehlmeier S, *et al.* 2021. *Leukemia.* Online ahead of prin. [PubMed](#)
32. Konduru NV, *et al.* 2021. *Nanotheranostics.* 5:309. [PubMed](#)
33. Luque-Martin R, *et al.* 2021. *J Immunol.* 207:555. [PubMed](#)
34. Sun Z, *et al.* 2013. *PLoS One.* 8:74672. [PubMed](#)
35. Bigley V, *et al.* 2015. *J Leukoc Biol.* 97:627. [PubMed](#)
36. Fu Y, *et al.* 2021. *Cell Reports.* 36(2):109344. [PubMed](#)
37. Halim TYF *et al.* 2018. *Immunity.* 48(6):1195-1207. [PubMed](#)
38. Jardine L, *et al.* 2019. *Nat Commun.* 10:1999. [PubMed](#)
39. Sade-Feldman M, *et al.* 2016. *Clin Cancer Res.* 22(23):5661-5672. [PubMed](#)
40. Qiu X, *et al.* 2022. *Cell.* 185:690. [PubMed](#)
41. Zhai Y, *et al.* 2018. *Autophagy.* 1.714583333. [PubMed](#)
42. Thurlow L, *et al.* 2010. *Infect Immun.* 78:4936. [PubMed](#)
43. Julian Buchrieser, William James, Michael D. Moore 2017. *Stem Cell Reports.* 8(2):334-345. [PubMed](#)
44. Wu X, *et al.* 2022. *Front Immunol.* 13:849493. [PubMed](#)
45. Ren X, *et al.* 2021. *Cell Death Dis.* 12:484. [PubMed](#)

RRID

AB_314161 (BioLegend Cat. No. 301309)
AB_314162 (BioLegend Cat. No. 301310)
AB_2564134 (BioLegend Cat. No. 301350)

Antigen Details

Structure	Integrin, type I transmembrane glycoprotein, associates with integrin β_2 (CD18), 165-170 kD
Distribution	Granulocytes, monocytes/macrophages, dendritic cells, NK cells, subset of T cells, subset of B cells
Function	Adhesion, phagocytosis, chemotaxis, neutrophil activation
Ligand/Receptor	ICAM-1(CD54), ICAM-2 (CD102), ICAM-4, CD14, CD23, heparin, iC3b, fibrinogen, factor X

Cell Type	B cells, Dendritic cells, Granulocytes, Macrophages, Monocytes, Neutrophils, NK cells, T cells, Tregs
Biology Area	Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity, Neuroscience, Neuroscience Cell Markers
Molecular Family	Adhesion Molecules, CD Molecules
Antigen References	1. Stewart M, <i>et al.</i> 1995. <i>Curr Opin Cell Biol.</i> 7:690.
Gene ID	3684


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

APC anti-human CD11b, Biotin anti-human CD11b, PE anti-human CD11b, PE/Cyanine5 anti-human CD11b, Purified anti-human CD11b, Pacific Blue™ anti-human CD11b, Alexa Fluor® 488 anti-human CD11b, Alexa Fluor® 647 anti-human CD11b, PE/Cyanine7 anti-human CD11b, PerCP/Cyanine5.5 anti-human CD11b, Brilliant Violet 421™ anti-human CD11b, Brilliant Violet 570™ anti-human CD11b, FITC anti-human CD11b, Brilliant Violet 605™ anti-human CD11b, Brilliant Violet 510™ anti-human CD11b, Brilliant Violet 650™ anti-human CD11b, Purified anti-human CD11b (Maxpar® Ready), Alexa Fluor® 594 anti-human CD11b, APC/Cyanine7 anti-human CD11b, Brilliant Violet 711™ anti-human CD11b, Brilliant Violet 785™ anti-human CD11b, PE/Dazzle™ 594 anti-human CD11b, APC/Fire™ 750 anti-human CD11b, TotalSeq™-A0161 anti-human CD11b, Alexa Fluor® 700 anti-human CD11b, TotalSeq™-B0161 anti-human CD11b, TotalSeq™-C0161 anti-human CD11b, Ultra-LEAF™ Purified anti-human CD11b, TotalSeq™-D0161 anti-human CD11b, GMP PE/Cyanine7 anti-human CD11b, GMP PE anti-human CD11b, Spark UV™ 387 anti-human CD11b, GMP PerCP/Cyanine5.5 anti-human CD11b, GMP APC anti-human CD11b

Product Data



Human peripheral blood granulocytes stained with ICRF44 APC

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587